应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
SPRC SciSparc Ltd.
休市中 03-20 16:00:00 EDT
4.63
-0.03
-0.64%
盘后
4.63
+0.00
0.00%
19:51 EDT
最高
4.63
最低
4.20
成交量
5,685
今开
4.34
昨收
4.66
日振幅
9.23%
总市值
261.83万
流通市值
209.83万
总股本
56.55万
成交额
2.52万
换手率
1.25%
流通股本
45.32万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
SciSparc与Neurothera Labs及Clearmind Medicine合作 推动抑郁症疗法专利申请
美股速递 · 03-16
SciSparc与Neurothera Labs及Clearmind Medicine合作 推动抑郁症疗法专利申请
SciSparc Ltd.合作企业Neurothera Labs宣布与Clearmind Medicine联合申请的国际专利公布,靶向减肥与脂肪肝新疗法
美股速递 · 03-12
SciSparc Ltd.合作企业Neurothera Labs宣布与Clearmind Medicine联合申请的国际专利公布,靶向减肥与脂肪肝新疗法
SciSparc子公司Neurothera Labs签署最终协议,收购量子临床试验先驱Cliniquantum多数股权
美股速递 · 03-10
SciSparc子公司Neurothera Labs签署最终协议,收购量子临床试验先驱Cliniquantum多数股权
SciSparc成功完成知识产权组合收购,加速推进即时商业化进程
美股速递 · 01-26
SciSparc成功完成知识产权组合收购,加速推进即时商业化进程
SciSparc:Neurothera Labs签署非绑定条款清单以收购量子算法生物数据分析公司多数股份
美股速递 · 2025-12-02
SciSparc:Neurothera Labs签署非绑定条款清单以收购量子算法生物数据分析公司多数股份
SciSparc计划通过收购获批的知识产权组合进军数十亿美元的胃食管反流设备市场
美股速递 · 2025-12-01
SciSparc计划通过收购获批的知识产权组合进军数十亿美元的胃食管反流设备市场
SciSparc Ltd:签署证券购买协议,计划以每股1.75美元发行129万普通股
美股速递 · 2025-11-28
SciSparc Ltd:签署证券购买协议,计划以每股1.75美元发行129万普通股
SciSparc股价攀升26%;公司将收购Xylo的医疗器械专利及知识产权
美股速递 · 2025-11-26
SciSparc股价攀升26%;公司将收购Xylo的医疗器械专利及知识产权
SciSparc股价在盘前上涨27.5%;公司将从Xylo购买一批专利、商标和知识产权
美股速递 · 2025-11-26
SciSparc股价在盘前上涨27.5%;公司将从Xylo购买一批专利、商标和知识产权
SciSparc:Neurothera Labs与Clearmind Medicine合作申请以色列专利,开发新型非致幻神经塑造剂用于抑郁症治疗
美股速递 · 2025-11-20
SciSparc:Neurothera Labs与Clearmind Medicine合作申请以色列专利,开发新型非致幻神经塑造剂用于抑郁症治疗
N2OFF与针对难治性胰腺癌和肺癌的癌症药物研发公司完成合并
美股速递 · 2025-10-30
N2OFF与针对难治性胰腺癌和肺癌的癌症药物研发公司完成合并
SciSparc宣布完成对多伦多证券交易所V板上市公司的收购,该公司已获得其先进临床阶段的药品组合
美股速递 · 2025-10-24
SciSparc宣布完成对多伦多证券交易所V板上市公司的收购,该公司已获得其先进临床阶段的药品组合
SciSparc宣布以N2OFF收购其控股子公司Mitocarex,推动对胰腺癌和非小细胞肺癌等耐药癌症的药物发现
美股速递 · 2025-10-24
SciSparc宣布以N2OFF收购其控股子公司Mitocarex,推动对胰腺癌和非小细胞肺癌等耐药癌症的药物发现
SciSparc与Clearmind合作推动美国专利申请公布,聚焦暴饮暴食行为障碍
美股速递 · 2025-10-20
SciSparc与Clearmind合作推动美国专利申请公布,聚焦暴饮暴食行为障碍
SciSparc签署最终协议,将收购一家在TSXV上市的公司并转让其先进临床阶段的制药投资组合
美股速递 · 2025-10-15
SciSparc签署最终协议,将收购一家在TSXV上市的公司并转让其先进临床阶段的制药投资组合
SciSparc Ltd.:N2off股东批准与SciSparc控股子公司Mitocarex合并,该药物发现公司专注于耐药性癌症研究,包括胰腺癌和非小细胞肺癌
美股速递 · 2025-09-30
SciSparc Ltd.:N2off股东批准与SciSparc控股子公司Mitocarex合并,该药物发现公司专注于耐药性癌症研究,包括胰腺癌和非小细胞肺癌
N2OFF, Inc股东批准与专注耐药性癌症药物研发公司的合并交易
美股速递 · 2025-09-26
N2OFF, Inc股东批准与专注耐药性癌症药物研发公司的合并交易
Scisparc Ltd.盘中异动 快速跳水6.79%
市场透视 · 2025-02-19
Scisparc Ltd.盘中异动 快速跳水6.79%
Scisparc Ltd.盘中异动跌6.68% 振幅达7.98%
市场透视 · 2025-02-18
Scisparc Ltd.盘中异动跌6.68% 振幅达7.98%
Scisparc Ltd.盘中异动 大幅下挫5.16%报0.502美元
市场透视 · 2025-02-14
Scisparc Ltd.盘中异动 大幅下挫5.16%报0.502美元
加载更多
公司概况
公司名称:
SciSparc Ltd.
所属市场:
NASDAQ
上市日期:
--
主营业务:
SciSparc Ltd.是一家制药公司,于2004年8月23日在以色列注册成立并开始运营。公司是一家临床专业的制药公司。该公司的重点是创建和加强基于大麻素疗法的技术和资产组合。基于此,公司目前正致力于以下基于Δ9-四氢大麻酚(THC)和非精神活性大麻酚(CBD)的开发项目:THX-110用于治疗抽动秽语综合征(TS)和阻塞性睡眠呼吸暂停症;THX-160用于治疗慢性和急性疼痛;THX-210用于治疗慢性和急性疼痛自闭症谱系障碍和癫痫的治疗。
发行价格:
--
{"stockData":{"symbol":"SPRC","market":"US","secType":"STK","nameCN":"SciSparc Ltd.","latestPrice":4.63,"timestamp":1774036800000,"preClose":4.66,"halted":0,"volume":5685,"hourTrading":{"tag":"盘后","latestPrice":4.63,"preClose":4.63,"latestTime":"19:51 EDT","volume":4,"amount":18.37,"timestamp":1774050693810,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.0064377682403434005,"floatShares":453200,"shares":565500,"eps":-21.520779,"marketStatus":"休市中","change":-0.03,"latestTime":"03-20 16:00:00 EDT","open":4.34,"high":4.63,"low":4.2,"amount":25182.861555,"amplitude":0.092275,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-21.520779,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1774252800000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":4.66,"preHourTrading":{"tag":"盘前","latestPrice":4.63,"preClose":4.66,"latestTime":"09:22 EDT","volume":94,"amount":436.710586,"timestamp":1774012948176,"change":-0.03,"changeRate":-0.006438,"amplitude":0.100794},"postHourTrading":{"tag":"盘后","latestPrice":4.63,"preClose":4.63,"latestTime":"19:51 EDT","volume":4,"amount":18.37,"timestamp":1774050693810,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.1966509546285829},"requestUrl":"/m/hq/s/SPRC","defaultTab":"news","newsList":[{"id":"1108138371","title":"SciSparc与Neurothera Labs及Clearmind Medicine合作 推动抑郁症疗法专利申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1108138371","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108138371?lang=zh_cn&edition=full","pubTime":"2026-03-16 20:35","pubTimestamp":1773664511,"startTime":"0","endTime":"0","summary":"SciSparc Ltd.宣布,其与Neurothera Labs及Clearmind Medicine的合作已取得重要进展,三方共同提交了一项针对抑郁症治疗方法的专利申请。这一合作旨在结合各方在神经科学和药物研发领域的专长,开发创新的治疗方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRC","BK4139","BK4007"],"gpt_icon":0},{"id":"1101461005","title":"SciSparc Ltd.合作企业Neurothera Labs宣布与Clearmind Medicine联合申请的国际专利公布,靶向减肥与脂肪肝新疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=1101461005","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101461005?lang=zh_cn&edition=full","pubTime":"2026-03-12 19:57","pubTimestamp":1773316636,"startTime":"0","endTime":"0","summary":"SciSparc Ltd.的合作方Neurothera Labs宣布,其与Clearmind Medicine共同开发的一项针对减重及脂肪肝疾病的新型疗法国际专利已正式公布。该专利标志着双方在代谢疾病治疗领域的合作取得重要进展,为开发创新疗法奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRC","BK4139","BK4007"],"gpt_icon":0},{"id":"1176827418","title":"SciSparc子公司Neurothera Labs签署最终协议,收购量子临床试验先驱Cliniquantum多数股权","url":"https://stock-news.laohu8.com/highlight/detail?id=1176827418","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176827418?lang=zh_cn&edition=full","pubTime":"2026-03-10 21:28","pubTimestamp":1773149305,"startTime":"0","endTime":"0","summary":"SciSparc Ltd. (SPRC) 宣布,其持股75%的子公司Neurothera Labs已正式签署最终协议,将收购Cliniquantum的多数股权。Cliniquantum是一家专注于量子计算技术应用于临床实验领域的创新公司。此次收购标志着SciSparc在推进创新疗法和临床开发平台方面迈出重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","SPRC"],"gpt_icon":0},{"id":"1149412818","title":"SciSparc成功完成知识产权组合收购,加速推进即时商业化进程","url":"https://stock-news.laohu8.com/highlight/detail?id=1149412818","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149412818?lang=zh_cn&edition=full","pubTime":"2026-01-26 21:14","pubTimestamp":1769433252,"startTime":"0","endTime":"0","summary":"SciSparc有限公司已顺利完成对知识产权资产组合的收购工作,标志着公司正式迈入即时商业化阶段。此次战略性收购将显著增强公司的研发实力与市场竞争力,为后续产品快速落地奠定坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRC","BK4007","BK4139"],"gpt_icon":0},{"id":"1105353374","title":"SciSparc:Neurothera Labs签署非绑定条款清单以收购量子算法生物数据分析公司多数股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1105353374","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105353374?lang=zh_cn&edition=full","pubTime":"2025-12-02 22:29","pubTimestamp":1764685756,"startTime":"0","endTime":"0","summary":"SciSparc:Neurothera Labs签署非绑定条款清单以收购量子算法生物数据分析公司多数股份","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRC","BK4139","BK4007"],"gpt_icon":0},{"id":"1188168411","title":"SciSparc计划通过收购获批的知识产权组合进军数十亿美元的胃食管反流设备市场","url":"https://stock-news.laohu8.com/highlight/detail?id=1188168411","media":"美股速递","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188168411?lang=zh_cn&edition=full","pubTime":"2025-12-01 21:32","pubTimestamp":1764595931,"startTime":"0","endTime":"0","summary":"SciSparc计划通过收购获批的知识产权组合进军数十亿美元的胃食管反流设备市场","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","SPRC"],"gpt_icon":0},{"id":"1198992218","title":"SciSparc Ltd:签署证券购买协议,计划以每股1.75美元发行129万普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1198992218","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198992218?lang=zh_cn&edition=full","pubTime":"2025-11-28 19:15","pubTimestamp":1764328508,"startTime":"0","endTime":"0","summary":"SciSparc Ltd:签署证券购买协议,计划以每股1.75美元发行129万普通股","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRC","BK4139","BK4007"],"gpt_icon":0},{"id":"1181782798","title":"SciSparc股价攀升26%;公司将收购Xylo的医疗器械专利及知识产权","url":"https://stock-news.laohu8.com/highlight/detail?id=1181782798","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181782798?lang=zh_cn&edition=full","pubTime":"2025-11-26 22:33","pubTimestamp":1764167589,"startTime":"0","endTime":"0","summary":"SciSparc股价攀升26%;公司将收购Xylo的医疗器械专利及知识产权","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","SPRC","BK4139"],"gpt_icon":0},{"id":"1101624999","title":"SciSparc股价在盘前上涨27.5%;公司将从Xylo购买一批专利、商标和知识产权","url":"https://stock-news.laohu8.com/highlight/detail?id=1101624999","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101624999?lang=zh_cn&edition=full","pubTime":"2025-11-26 20:44","pubTimestamp":1764161063,"startTime":"0","endTime":"0","summary":"SciSparc股价在盘前上涨27.5%;公司宣布将从Xylo购买一批专利、商标和知识产权。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SPRC","BK4007"],"gpt_icon":0},{"id":"1158315480","title":"SciSparc:Neurothera Labs与Clearmind Medicine合作申请以色列专利,开发新型非致幻神经塑造剂用于抑郁症治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1158315480","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158315480?lang=zh_cn&edition=full","pubTime":"2025-11-20 19:43","pubTimestamp":1763639008,"startTime":"0","endTime":"0","summary":"SciSparc:Neurothera Labs与Clearmind Medicine合作申请以色列专利,开发新型非致幻神经塑造剂用于抑郁症治疗","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SPRC","BK4007"],"gpt_icon":0},{"id":"1101805950","title":"N2OFF与针对难治性胰腺癌和肺癌的癌症药物研发公司完成合并","url":"https://stock-news.laohu8.com/highlight/detail?id=1101805950","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101805950?lang=zh_cn&edition=full","pubTime":"2025-10-30 21:25","pubTimestamp":1761830722,"startTime":"0","endTime":"0","summary":"N2OFF与针对难治性胰腺癌和肺癌的癌症药物研发公司完成合并。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4093","BK4539","BK4139","NITO","BK4007","SPRC"],"gpt_icon":0},{"id":"1142328275","title":"SciSparc宣布完成对多伦多证券交易所V板上市公司的收购,该公司已获得其先进临床阶段的药品组合","url":"https://stock-news.laohu8.com/highlight/detail?id=1142328275","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142328275?lang=zh_cn&edition=full","pubTime":"2025-10-24 19:56","pubTimestamp":1761306993,"startTime":"0","endTime":"0","summary":"SciSparc宣布完成对多伦多证券交易所V板上市公司的收购,该公司已获得其先进临床阶段的药品组合。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRC","BK4007","BK4139"],"gpt_icon":0},{"id":"1155594061","title":"SciSparc宣布以N2OFF收购其控股子公司Mitocarex,推动对胰腺癌和非小细胞肺癌等耐药癌症的药物发现","url":"https://stock-news.laohu8.com/highlight/detail?id=1155594061","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1155594061?lang=zh_cn&edition=full","pubTime":"2025-10-24 04:03","pubTimestamp":1761249817,"startTime":"0","endTime":"0","summary":"SciSparc宣布以N2OFF收购其控股子公司Mitocarex的交易已完成,这将推动针对包括胰腺癌和非小细胞肺癌在内的耐药癌症的药物研发。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4093","NITO","SPRC","BK4139","BK4007"],"gpt_icon":0},{"id":"1192639784","title":"SciSparc与Clearmind合作推动美国专利申请公布,聚焦暴饮暴食行为障碍","url":"https://stock-news.laohu8.com/highlight/detail?id=1192639784","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192639784?lang=zh_cn&edition=full","pubTime":"2025-10-20 19:42","pubTimestamp":1760960529,"startTime":"0","endTime":"0","summary":"SciSparc与Clearmind合作推动美国专利申请的公布,专注于暴饮暴食行为障碍的治疗。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMND","BK4007","BK4139","SPRC"],"gpt_icon":0},{"id":"1127390846","title":"SciSparc签署最终协议,将收购一家在TSXV上市的公司并转让其先进临床阶段的制药投资组合","url":"https://stock-news.laohu8.com/highlight/detail?id=1127390846","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1127390846?lang=zh_cn&edition=full","pubTime":"2025-10-15 19:05","pubTimestamp":1760526330,"startTime":"0","endTime":"0","summary":"SciSparc签署最终协议,将收购一家在TSXV上市的公司并转让其先进临床阶段的制药投资组合","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","SPRC"],"gpt_icon":0},{"id":"1167534909","title":"SciSparc Ltd.:N2off股东批准与SciSparc控股子公司Mitocarex合并,该药物发现公司专注于耐药性癌症研究,包括胰腺癌和非小细胞肺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1167534909","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167534909?lang=zh_cn&edition=full","pubTime":"2025-09-30 04:04","pubTimestamp":1759176262,"startTime":"0","endTime":"0","summary":"SciSparc Ltd.:N2off股东批准与SciSparc控股子公司Mitocarex合并,该药物发现公司专注于耐药性癌症研究,包括胰腺癌和非小细胞肺癌","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPRC","BK4007","BK4139"],"gpt_icon":0},{"id":"1195339865","title":"N2OFF, Inc股东批准与专注耐药性癌症药物研发公司的合并交易","url":"https://stock-news.laohu8.com/highlight/detail?id=1195339865","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195339865?lang=zh_cn&edition=full","pubTime":"2025-09-26 04:03","pubTimestamp":1758830597,"startTime":"0","endTime":"0","summary":"N2OFF, Inc股东已正式批准与一家专门从事药物发现的公司进行合并。该药物研发公司主要致力于开发针对耐药性癌症的创新疗法,重点关注胰腺癌和非小细胞肺癌等难治性肿瘤领域的药物研究与开发。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4093","BK4539","BK4139","SPRC","NITO"],"gpt_icon":0},{"id":"2512854194","title":"Scisparc Ltd.盘中异动 快速跳水6.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512854194","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512854194?lang=zh_cn&edition=full","pubTime":"2025-02-19 23:02","pubTimestamp":1739977362,"startTime":"0","endTime":"0","summary":"北京时间2025年02月19日23时02分,Scisparc Ltd.股票出现异动,股价大幅跳水6.79%。截至发稿,该股报0.460美元/股,成交量8.6211万股,换手率0.80%,振幅3.87%。Scisparc Ltd.股票所在的生物技术行业中,整体涨幅为0.49%。其相关个股中,Osr Holdings, Inc.、Osr Holdings Inc C/Wts 02/09/2028 、Aditxt, Inc.涨幅较大,Aditxt, Inc.、Alzamend Neuro, Inc.、Osr Holdings, Inc.较为活跃,换手率分别为362.50%、223.90%、82.90%,振幅较大的相关个股有Osr Holdings Inc C/Wts 02/09/2028 、Osr Holdings, Inc.、Allogene Therapeutics, Inc.,振幅分别为207.68%、119.61%、36.97%。Scisparc Ltd.公司简介:SciSparc Ltd 是一家专业临床阶段制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219230243a24c028f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219230243a24c028f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BK4139","SPRC"],"gpt_icon":0},{"id":"2512166011","title":"Scisparc Ltd.盘中异动跌6.68% 振幅达7.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512166011","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512166011?lang=zh_cn&edition=full","pubTime":"2025-02-18 23:06","pubTimestamp":1739891194,"startTime":"0","endTime":"0","summary":"北京时间2025年02月18日23时06分,Scisparc Ltd.股票出现波动,股价大幅下挫6.68%。截至发稿,该股报0.465美元/股,成交量199.271万股,换手率18.40%,振幅7.98%。Scisparc Ltd.股票所在的生物技术行业中,整体涨幅为0.62%。其相关个股中,Estrella Immunopharma Inc C/Wts 29/09/2028、Solid Biosciences Inc.、Allogene Therapeutics, Inc.涨幅较大,Aditxt, Inc.、Solid Biosciences Inc.、Moleculin Biotech, Inc.较为活跃,换手率分别为338.80%、129.09%、120.41%,振幅较大的相关个股有Estrella Immunopharma Inc C/Wts 29/09/2028、Psyence Biomedical Ltd C/Wts 25/01/2029、Allogene Therapeutics, Inc.,振幅分别为148.75%、41.79%、35.54%。Scisparc Ltd.公司简介:SciSparc Ltd 是一家专业临床阶段制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021823063596279e6c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021823063596279e6c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SPRC","BK4007"],"gpt_icon":0},{"id":"2511069609","title":"Scisparc Ltd.盘中异动 大幅下挫5.16%报0.502美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2511069609","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511069609?lang=zh_cn&edition=full","pubTime":"2025-02-14 22:44","pubTimestamp":1739544265,"startTime":"0","endTime":"0","summary":"北京时间2025年02月14日22时44分,Scisparc Ltd.股票出现异动,股价大幅跳水5.16%。截至发稿,该股报0.502美元/股,成交量2.0343万股,换手率0.19%,振幅4.73%。Scisparc Ltd.股票所在的生物技术行业中,整体涨幅为0.28%。其相关个股中,Moleculin Biotech, Inc.、Cns Pharmaceuticals, Inc.、Virpax Pharmaceuticals, Inc.涨幅较大,Moleculin Biotech, Inc.、Cns Pharmaceuticals, Inc.、Virpax Pharmaceuticals, Inc.较为活跃,换手率分别为1626.02%、450.49%、409.59%,振幅较大的相关个股有Moleculin Biotech, Inc.、Cns Pharmaceuticals, Inc.、Klotho Neurosciences, Inc.,振幅分别为66.93%、32.93%、32.49%。Scisparc Ltd.公司简介:SciSparc Ltd 是一家专业临床阶段制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250214224425abcf098f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250214224425abcf098f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SPRC","BK4007","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.scisparc.com","stockEarnings":[{"period":"1week","weight":0.0619},{"period":"1month","weight":-0.0871},{"period":"3month","weight":-0.6476},{"period":"6month","weight":-0.8922},{"period":"1year","weight":-0.9277},{"period":"ytd","weight":-0.6217}],"compareEarnings":[{"period":"1week","weight":-0.0207},{"period":"1month","weight":-0.055},{"period":"3month","weight":-0.047},{"period":"6month","weight":-0.0228},{"period":"1year","weight":0.1469},{"period":"ytd","weight":-0.0489}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"SciSparc Ltd.是一家制药公司,于2004年8月23日在以色列注册成立并开始运营。公司是一家临床专业的制药公司。该公司的重点是创建和加强基于大麻素疗法的技术和资产组合。基于此,公司目前正致力于以下基于Δ9-四氢大麻酚(THC)和非精神活性大麻酚(CBD)的开发项目:THX-110用于治疗抽动秽语综合征(TS)和阻塞性睡眠呼吸暂停症;THX-160用于治疗慢性和急性疼痛;THX-210用于治疗慢性和急性疼痛自闭症谱系障碍和癫痫的治疗。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.075328},{"month":2,"riseRate":0.2,"avgChangeRate":-0.14034},{"month":3,"riseRate":0,"avgChangeRate":-0.281398},{"month":4,"riseRate":0.25,"avgChangeRate":0.005877},{"month":5,"riseRate":0.5,"avgChangeRate":-0.039695},{"month":6,"riseRate":0,"avgChangeRate":-0.156179},{"month":7,"riseRate":0,"avgChangeRate":-0.243864},{"month":8,"riseRate":0,"avgChangeRate":-0.467442},{"month":9,"riseRate":0.25,"avgChangeRate":0.236982},{"month":10,"riseRate":0.75,"avgChangeRate":0.077569},{"month":11,"riseRate":0.5,"avgChangeRate":0.007929},{"month":12,"riseRate":0.25,"avgChangeRate":-0.09099}],"exchange":"NASDAQ","name":"SciSparc Ltd.","nameEN":"SciSparc Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"SciSparc Ltd.(SPRC)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供SciSparc Ltd.(SPRC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"SciSparc Ltd.,SPRC,SciSparc Ltd.股票,SciSparc Ltd.股票老虎,SciSparc Ltd.股票老虎国际,SciSparc Ltd.行情,SciSparc Ltd.股票行情,SciSparc Ltd.股价,SciSparc Ltd.股市,SciSparc Ltd.股票价格,SciSparc Ltd.股票交易,SciSparc Ltd.股票购买,SciSparc Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"SciSparc Ltd.(SPRC)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供SciSparc Ltd.(SPRC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}